Thanks for posting - have been following from afar and very interested in this area. Sorry for the naive questions, I am a software guy new to biotech.

- How have things looked since passage? Has there been a lot of interest from companies and patients or is demand the bottleneck? Not that many people in Montana...

- What sort of new business models does this open up? e.g. Roivant for abandoned phase 1 assets?

- Does this lower the barrier for treating new indications, e.g. age related conditions like sarcopenia?

- Any particular rules on telehealth?

- Strong demand from biotechs (first approval decision made and public, Parley Neurotech), we're talking several dozens with $5-300m in funding each

- Clinics a bit more lagging, because licensing takes up to 90 days; in a few weeks we hopefully see the first clinic

- Business models: I'd personally be very excited about open-sourcing phase-1 assets to encourage further development to better drugs by more people

- Yes, this was an explicit hope from the geroscience community to address gaps e.g. in frailty, age-induces diseases with multiple possible endpoints

- No explicit rules on telehealth, but administration needs to be in Montana under a brick-and-mortar clinic; telehealth probably possible within those limits